Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.

about

Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.

Item

http://www.wikidata.org/entity/Q41573231

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cessation of immunosuppression ...... in renal transplant patients.

@en

type

Item

label

Cessation of immunosuppression ...... in renal transplant patients.

@en

prefLabel

Cessation of immunosuppression ...... in renal transplant patients.

@en

P1476

Cessation of immunosuppression ...... s in renal transplant patients

@en

P2093

David W Johnson

http://www.w3.org/2001/XMLSchema#string

Devinder S Gill

http://www.w3.org/2001/XMLSchema#string

Emma Taylor

http://www.w3.org/2001/XMLSchema#string

Maher K Gandhi

http://www.w3.org/2001/XMLSchema#string

Matthew J Hourigan

http://www.w3.org/2001/XMLSchema#string

Nicole Isbel

http://www.w3.org/2001/XMLSchema#string

Paula Marlton

http://www.w3.org/2001/XMLSchema#string

Scott B Campbell

http://www.w3.org/2001/XMLSchema#string

P2860

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

Lymphoproliferative disease after renal transplantation in Australia and New Zealand.

Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.

Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines.

Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines.

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients.

P304

1774-1779

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFV260

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Carmel M. Hawley

Peter Mollee

Mark Jones

P577

2015-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26188340

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression